Lipfendra (enlicitide) is the first oral PCSK9 inhibitor, approved by the FDA in July 2026 at a list price of $315 a month.
The post The First Oral PCSK9 Inhibitor Is Here — But What Does It Actually Cost? appeared first on The Hearty Soul.
Lipfendra (enlicitide) is the first oral PCSK9 inhibitor, approved by the FDA in July 2026 at a list price of $315 a month.
The post The First Oral PCSK9 Inhibitor Is Here — But What Does It Actually Cost? appeared first on The Hearty Soul.